Search Results - "Bolda, Federica"

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia by Malagola, Michele, Polverelli, Nicola, Beghin, Alessandra, Bolda, Federica, Comini, Marta, Farina, Mirko, Morello, Enrico, Radici, Vera, Accorsi Buttini, Eugenia, Bernardi, Simona, Re, Federica, Leoni, Alessandro, Bonometti, Davide, Brugnoni, Duilio, Lanfranchi, Arnalda, Russo, Domenico

“…Minimal residual disease (MRD) monitoring is an important tool to optimally address post-transplant management of acute myeloid leukemia (AML) patients. We…”
Get full text

Long-Lasting Production of New T and B Cells and T-Cell Repertoire Diversity in Patients with Primary Immunodeficiency Who Had Undergone Stem Cell Transplantation: A Single-Centre Experience by Imberti, Luisa, Caimi, Luigi, Giustini, Viviana, Bertoli, Diego, Serana, Federico, Bolda, Federica, Lanfranchi, Arnalda, Sottini, Alessandra, Valotti, Monica, Vaglio Tessitore, Marion

“…Levels of Kappa-deleting recombination excision circles (KRECs), T-cell receptor excision circles (TRECs), and T-cell repertoire diversity were evaluated in…”
Get full text

Abstract 17: IL10R Deficiency and Hemopoietic Cell Transplantation (HCT): Outcome of 2 Patients Treated in a Single Center with CBU HCT by Rossi, Stefano, Baresi, Giulia, Soncini, Elena, Tessarin, Giulio, Pintabona, Vincenzo, Carracchia, Giulia, Maffeis, Marianna, Fuoti, Maurizio, Albrici, Giulia, Beghin, Alessandra, Comini, Marta, Bolda, Federica, Lanfranchi, Arnalda, Porta, Fulvio

Get full text

Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient by Lanfranchi, Arnalda, Lougaris, Vassilios, Notarangelo, Lucia Dora, Soncini, Elena, Comini, Marta, Beghin, Alessandra, Bolda, Federica, Montanelli, Alessandro, Imberti, Luisa, Porta, Fulvio

“…We describe the case of a child affected by severe combined immunodeficiency (SCID) with adenosine deaminase (ADA) deficiency showing a maternal T-cell…”
Get full text

Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience by Baffelli, Renata, Notarangelo, Lucia D., Imberti, Luisa, Hershfield, Michael S., Serana, Federico, Santisteban, Ines, Bolda, Federica, Porta, Fulvio, Lanfranchi, Arnalda

“…Purpose We carried out a retrospective analysis of 27 patients with Adenosine Deaminase (ADA) deficiency diagnosed in a single center from 1997 to the 2013,…”
Get full text

CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases by Porta, Fulvio, Comini, Marta, Soncini, Elena, Carracchia, Giulia, Maffeis, Marianna, Pintabona, Vincenzo, Bolda, Federica, Beghin, Alessandra, Schumacher, Richard Fabian, Lanfranchi, Arnalda

“…•MUD HSCT is an option in PID and hematological diseases.•CD34+ selection is performed even on MUD, since patients are children mostly with PID.•The aim is…”
Get full text

Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia by Pagani, Ilaria Stefania, Spinelli, Orietta, Pirrone, Cristina, Pigni, Diana, Lupoli, Sara, D'Avila, Francesca, Barcella, Matteo, Boroni, Chiara, Intermesoli, Tamara, Giussani, Ursula, Bolda, Federica, Pasquali, Francesco, Lo Curto, Francesco, Lanfranchi, Arnalda, Porta, Fulvio, Barlassina, Cristina, Rambaldi, Alessandro, Porta, Giovanni

“…Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia (CML), effectively prolonging overall survival. Because discontinuation of…”
Get full text

Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia by Pagani, Ilaria S, Spinelli, Orietta, Mattarucchi, Elia, Pirrone, Cristina, Pigni, Diana, Amelotti, Elisabetta, Lilliu, Silvia, Boroni, Chiara, Intermesoli, Tamara, Giussani, Ursula, Caimi, Luigi, Bolda, Federica, Baffelli, Renata, Candi, Eleonora, Pasquali, Francesco, Lo Curto, Francesco, Lanfranchi, Arnalda, Porta, Fulvio, Rambaldi, Alessandro, Porta, Giovanni

“…Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia, effectively prolonging overall survival. Because discontinuation of…”
Get full text